Apellis posts Syfovre 24-month data analyses

24 April 2023

US retinal disease specialist Apellis Pharmaceuticals (Nasdaq: APLS) has announced post hoc analyses from the 24-month, Phase III OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Syfovre was approved by the US Food and Drug Administration for this indication in February this year. Marketed as Empaveli, the systemic pegcetacoplan was previously approved by the FDA in 2021 for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening blood disease.

The latest analyses were reported during oral presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place April 23-27 in New Orleans, USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK